Endometrial Hyperplasia Without Atypia Clinical Trial
Official title:
Vaginal Micronized Progesterone or Levonorgestrel-releasing Intrauterine System (LNG-IUS) for Treatment of Non-atypical Endometrial Hyperplasia: A Prospective Randomized Trial
The purpose of this study is to compare the efficacy of the vaginal micronized progesterone and Levonorgestrel-releasing Intrauterine System for treatment of non-atypical endometrial hyperplasia in premenopausal women.
Vaginal use of micronized progesterone in the treatment of endometrial hyperplasia can result in better than oral administration, as it will remain away from the first pass effect, and depending on the local application. In this study, we aimed to compare this local treatment with Levonorgestrel-releasing Intrauterine System for treatment of non-atypical endometrial hyperplasia. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06115577 -
Endometrial Tissues and Mononuclear Cells Receptivity in Pathogenesis of Endometrial Proliferative Processes
|
||
| Not yet recruiting |
NCT06378489 -
The Use of Etonogestrel Contraceptive Implant as Treatment for Endometrial Hyperplasia Without Atypia: A Cohort Study
|
||
| Completed |
NCT01685762 -
Metformin for the Treatment of Endometrial Hyperplasia
|
Early Phase 1 | |
| Completed |
NCT03675139 -
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
|
Phase 3 |